OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01643772 |
Recruitment Status :
Completed
First Posted : July 18, 2012
Results First Posted : October 21, 2019
Last Update Posted : October 21, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain | Drug: Oxycodone hydrochloride | Phase 1 |
Single dose: The subjects will be randomized to receive a single dose of OxyNorm® immediate-release capsules 5, 10, and 20mg.
Multiple dose: The subjects will take 3 days OxyNorm® capsule 10mg, once every 6 hours, 10mg per dose. In the morning of the 4th day, the subjects will take single dose of OxyNorm® capsule 10mg. On the 5th day, all the subjects complete the study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 61 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | OxyNorm® Capsules (Immediate-Release) PK Study |
Study Start Date : | May 2011 |
Actual Primary Completion Date : | July 2012 |
Actual Study Completion Date : | July 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Oxycodone Hydrochloride 5 mg Capsules
Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
|
Drug: Oxycodone hydrochloride
The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
Other Name: OxyNorm® Capsules |
Experimental: Oxycodone Hydrochloride 10 mg Capsules
Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
|
Drug: Oxycodone hydrochloride
The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
Other Name: OxyNorm® Capsules |
Experimental: Oxycodone Hydrochloride 20 mg Capsules
Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
|
Drug: Oxycodone hydrochloride
The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
Other Name: OxyNorm® Capsules |
Experimental: Oxycodone Hydrochloride 10 mg Capsules(multi-dose)
Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
|
Drug: Oxycodone hydrochloride
The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
Other Name: OxyNorm® Capsules |
- AUC0-t and AUC0-∞ for Participants Who Received a Single Dose [ Time Frame: blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. ]To calculate AUC0-t AUC0-∞of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method.Plasma concentrations of Oxycodone Hydrochloride single dose 5mg,10mg,20mg will be analyzed.
- Cmax,Clast for Participants Who Received a Single Dose [ Time Frame: blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. ]To calculate Cmax,Clast of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg.
- Tmax,t1/2 for Participants Who Received a Single Dose [ Time Frame: blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. ]To calculate Tmax,t1/2 of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg.
- Clearance Rate for Participants Who Received a Single Dose [ Time Frame: blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. ]To calculate CL of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg.
- Vd for Participants Who Received a Single Dose [ Time Frame: blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. ]To calculate Apparent Distribution Volume (Vd) Vd of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg.
- ke for Participants Who Received a Single Dose [ Time Frame: blood sample at predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24hr post-dose. ]To calculate Terminal Elimination Rate (ke) of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in single dose 5mg,10mg,20mg.
- AUCss for Participants Who Received Multiple Dose [ Time Frame: Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. ]To calculate AUCss of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg.
- Css_min,Css_max and Css_av for Participants Who Received Multiple Dose [ Time Frame: Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. ]To calculate Css_min,Css_max and Css_av of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg.
- Tmax,t1/2 for Participants Who Received Multiple Dose [ Time Frame: Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. ]To calculate Tmax,t1/2 of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg.
- CL for Participants Who Received Multiple Dose [ Time Frame: Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. ]To calculate Clearance rate (CL) of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg.
- Fluctuation Index (DF) for Participants Who Received Multiple Dose [ Time Frame: Predose for the 1st, 2nd, 3rd day and predose,15min,30min,45min,1,1.5,2,3,4,6,8,12,24 post dose on the 4th day. ]To calculate Fluctuation index (DF) of Drug Valley and Peak Concentration of Oxycondone,Noroxycodone,Hydroxymorphine, Normethoxymorphone with Non-atrioventricular model method in multiple dose 10mg.
- The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) [ Time Frame: Pre-dose,post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h ]The excretion of drugs were calculated according to the concentration and volume of drugs in urine after single dose.
- Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) [ Time Frame: post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h ]Cumulative excretion of drugs were calculated according to the concentration and volume of drugs in urine after single dose.
- Average Cumulative Excretion Rate of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Single Dose) [ Time Frame: post dose 24h ]Average cumulative excretion rate of drugs were calculated according to the concentration and volume of drugs in urine after single dose.
- The Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Multiple Dose) [ Time Frame: Pre-dose,post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h on the 4th day ]The excretion of drugs were calculated according to the concentration and volume of drugs in urine after multiple dose on the 4th day.
- Cumulative Excretion of Oxycondone, Noroxycodone, Hydroxymorphine,Normethoxymorphone in Urine(Mutilple Dose) [ Time Frame: post dose0-2h,post dose2-4h,post dose4-8h,post dose8-12h,post dose12-24h on the 4th day ]Cumulative excretion of drugs were calculated according to the concentration and volume of drugs in urine after multiple dose on the 4th day .

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with pain, Multiple dose group should enroll the Patients with cancer pain;
- Patients aged >≥30 to ≤ 60 years;
- Body weight ≥ 45kg, and BMI range ≥19, <24;
- Karnofsky score ≥ 70;
- The results of liver function and kidney tests must meet the following criteria: ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25;
- The electrocardiogram examination results are normal;
- Patients must have given a written informed consent prior to this trial, and have the capability to complete every required test.
Exclusion Criteria:
- Have hypersensitivity history to any opioids;
- Have known hypersensitivity to any of compositions of the study drugs;
- Patients who are likely to have paralytic ileus or acute abdomen or to perform an operation on abdominal region;
- Patients with respiratory depression, cor pulmonale, or chronic bronchial asthma;
- Patients who are unable to stop taking monoamine oxidase inhibitor during this trial period or time lapses less than 2 weeks since drug withdrawal;
- Patients with hypercarbia;
- Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency;
- Patients with alcoholism or drug abuse history;
- Positive anti-HIV or syphilis antibody test result;
- Patients who are pregnant, or lactating;
- Urine screening before study is positive for opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids;
- Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within one month prior to the start of the study;
- Subjects who participated in a clinical research study within one month of study entry;
- Patients who are currently taking opioids.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01643772
China | |
Affiliated Hospital to Academy of Military Medical Science of China People's Liberation Army | |
Beijing, China |
Study Chair: | Mundipharma China Ltd. | Mundipharma China Ltd. |
Responsible Party: | Mundipharma (China) Pharmaceutical Co. Ltd |
ClinicalTrials.gov Identifier: | NCT01643772 |
Other Study ID Numbers: |
OXYC09-CN-102 |
First Posted: | July 18, 2012 Key Record Dates |
Results First Posted: | October 21, 2019 |
Last Update Posted: | October 21, 2019 |
Last Verified: | September 2019 |
Oxycodone Analgesics, Opioid Narcotics Central Nervous System Depressants |
Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents |